Climate Change Data

Egetis Therapeutics AB

Climate Impact & Sustainability Data (2011-01 to 2011-09, 2023, 2024)

Reporting Period: 2011-01 to 2011-09

Environmental Metrics

Social Achievements

  • Marie Bengtson hired as Clinical Project Director, and Erik Kinnman as medical expert and VP Investor Relations.

Climate Goals & Targets

Supply Chain Management

Climate-Related Risks & Opportunities

Reporting Period: 2023

Environmental Metrics

Total Carbon Emissions:Not disclosed
Scope 1 Emissions:Not disclosed
Scope 2 Emissions:Not disclosed
Scope 3 Emissions:Not disclosed
Renewable Energy Share:Not disclosed
Total Energy Consumption:Not disclosed
Water Consumption:Not disclosed
Waste Generated:Not disclosed
Carbon Intensity:Not disclosed

ESG Focus Areas

  • Not disclosed

Environmental Achievements

  • Not disclosed

Social Achievements

  • Launched disease awareness initiatives to support diagnosis of MCT8 deficiency
  • Over 190 patients are being treated with Emcitate in managed access programs

Governance Achievements

  • Not disclosed

Climate Goals & Targets

Long-term Goals:
  • Realize the full potential of our products via life-cycle management
  • Ensure fast and broad access to our products for the benefit of patients worldwide
  • Identify further assets that address the significant unmet medical need for patients with rare diseases
Medium-term Goals:
  • Commercialize Emcitate and Aladote through an inhouse organization in Europe/ North America and partnerships in RoW
Short-term Goals:
  • Successfully develop Emcitate for EU & US approvals in 2024/25 and Aladote post 2026

Environmental Challenges

  • Longer than anticipated review times for IRB/IEC and site contracting as well as the need for a substantial amendment of study documentation led to significant delays in site initiation.
  • Several factors affect completion of the ReTRIACt study e.g. patient type and availability, recruitment capacity, titration time
Mitigation Strategies
  • Egetis has taken steps to mitigate these factors and will update the market as soon as recruitment has been completed, and subsequently when top-line results and NDA filing can be expected

Supply Chain Management

Supplier Audits: Not disclosed

Responsible Procurement
  • Not disclosed

Climate-Related Risks & Opportunities

Physical Risks
  • Not disclosed
Transition Risks
  • Not disclosed
Opportunities
  • Not disclosed

Reporting Standards

Frameworks Used: Null

Certifications: Null

Third-party Assurance: Not disclosed

UN Sustainable Development Goals

  • Not disclosed

Not disclosed

Sustainable Products & Innovation

  • Not disclosed

Awards & Recognition

  • Not disclosed

Reporting Period: 2024

Environmental Metrics

Total Carbon Emissions:Not disclosed
Scope 1 Emissions:Not disclosed
Scope 2 Emissions:Not disclosed
Scope 3 Emissions:Not disclosed
Renewable Energy Share:Not disclosed
Total Energy Consumption:Not disclosed
Water Consumption:Not disclosed
Waste Generated:Not disclosed
Carbon Intensity:Not disclosed

ESG Focus Areas

  • Not disclosed

Environmental Achievements

  • Not disclosed

Social Achievements

  • Launched disease awareness initiatives to support diagnosis of MCT8 deficiency
  • Over 220 patients are being treated with Emcitate in managed access programs

Governance Achievements

  • Not disclosed

Climate Goals & Targets

Long-term Goals:
  • Realize the full potential of our products via life-cycle management
  • Ensure fast and broad access to our products for the benefit of patients worldwide
  • Identify further assets that address the significant unmet medical need for patients with rare diseases
Medium-term Goals:
  • Commercialize Emcitate and Aladote through an inhouse organization in Europe/ North America and partnerships in RoW
Short-term Goals:
  • Successfully develop Emcitate for EU & US approvals in 2024/25 and Aladote post 2026

Environmental Challenges

  • Not disclosed
Mitigation Strategies
  • Not disclosed

Supply Chain Management

Supplier Audits: Not disclosed

Responsible Procurement
  • Not disclosed

Climate-Related Risks & Opportunities

Physical Risks
  • Not disclosed
Transition Risks
  • Not disclosed
Opportunities
  • Not disclosed

Reporting Standards

Frameworks Used: Null

Certifications: Null

Third-party Assurance: Not disclosed

UN Sustainable Development Goals

  • Not disclosed

Not disclosed

Sustainable Products & Innovation

  • Not disclosed

Awards & Recognition

  • Not disclosed